Back to search results

Study of MZRW Herbal Supplement for Constipation in Cancer Survivors

This study is investigating whether an herbal supplement called MZRW can help cancer survivors who experience constipation. MZRW is a blend of several herbs, including Hemp Seed and Rhubarb. Researchers will compare MZRW to a placebo, which looks like MZRW but contains no active ingredients, to see if it improves spontaneous bowel movements (SBMs) over two weeks. They will also study how MZRW affects the gut microbiome (the community of microorganisms in your digestive system). You may be able to join if you are 18 or older, have a cancer diagnosis (any type or stage), and have completed most of your cancer treatments at least one month ago. The study aims to enroll 70 participants.

Study design
This is an interventional study comparing the MZRW herbal formula to a placebo. It plans to enroll 70 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint measures changes in bowel movements from baseline to week 2.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07091084

A Study of Herbal Supplements in Cancer Survivors With Constipation

Recruiting
NAAges 18+InterventionalTreatment
Memorial Sloan Kettering Cancer Center
~70 participants
Updated 2026-05-22 on ClinicalTrials.gov
What's tested:MZRW

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Difference of spontaneous bowel movements (SBMs) from baseline to week 2
Measured over 2 weeks

Conditions

Constipation
Cancer
Functional Constipation

Explore related trials

Functional constipationMalignant Neoplasm

Where it's being run

7 sites across 2 states
New York4
New Jersey3

Study leadership

  • Jun Mao, MD, MSCE · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Jun Mao, MD, MSCE
[email protected]
646-608-8552
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years or greater;
A diagnosis of cancer with no restrictions placed on type of cancer or stage;
Completed surgery, chemotherapy, immunotherapy, and/or radiotherapy, or an investigational therapy at least one month prior to study initiation. Patients on stable doses of hormone therapy or targeted therapies will not be excluded;
Karnofsky functional score of ≥ 60;
Cancer survivors who have met the Rome IV criteria (Table 3) of the symptoms of functional constipation which must include two or more of the following:
Straining more than 25% of defecations.
Lumpy or hard stools (7-point Bristol stool scale 1 or 2) more than 25% of defecations.
Sensation of incomplete evacuation more than one-fourth (25%) of defecations.
Sensation of anorectal obstruction/blockage more than one-fourth (25%) of defecations.
Manual maneuvers to facilitate more than one-fourth (25%) of defecations.
Fewer than three spontaneous bowel movements per week.
Loose stools are rarely present without the use of laxatives.
Insufficient criteria for irritable bowel syndrome.
Patient should be able to understand and complete all study assessments on their own
Patient should be able to understand and provide signed informed consent in English.

Exclusion

Patients who have allergic history to herbs or Chinese medicine;
Clinically significant abnormal liver (2 times the ULN for ALT or AST) and kidney disfunction(eGFR below 59 mL/min/1.73m² ) from recent laboratory test recorded in the medical record (within 2 month);
Patients who have any signs of bowel obstruction, or have high risk of bowel obstruction assessed by their treating physician, including factors such as tumor invasion into abdominal organs, recent abdominal surgery, and prior abdominal radiation therapy;
Patients who are prescribed opioid antagonists including methylnaltrexone, naloxegol and naldemedine for opioid induced constipation and required not to stop the medication;
Women who are pregnant, lactating, or not practicing proper contraception by patient report.Patient's should follow proper contraception guidelines for at least 30 days following last dose of the study drug.

What this trial measures

  • Difference of spontaneous bowel movements (SBMs) from baseline to week 22 weeks

    To evaluate the efficacy of a 2-week regimen of oral MZRW vs. placebo on spontaneous bowel movements (SBMs), in terms of SBM therapeutic response (primary efficacy endpoint), among cancer survivors with chronic constipation. SBM response is defined at week 2 as having an increase of ≥ 1 SBM/week from baseline.